Top
image credit: Freepik

Phase 2 trial shows COVID-19 recombinant protein vaccine elicits promising immunogenicity responses

October 19, 2021

Category:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus 19 (COVID-19), was first reported in Wuhan, China, in December 2019. Due to the rapid spread of the disease, the World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. The virus to date has been responsible for over 241 million infections and 4.9 million deaths and is continuing to spread despite the rapid global vaccination efforts.

One vaccine developed to fight the COVID-19 pandemic is the MVC-COV1901 recombinant protein subunit vaccine, based on the stabilized pre-fusion SARS-CoV-2 spike protein S-2P, adjuvanted with CpG 1018 and aluminium hydroxide.

Read More on The Medical News